https://doi.org/10.55788/96eeb9d2
Previous studies have shown that the extract of the South American fern polypodium leucotomos (PLE) is a powerful antioxidant due to its high content of phenolic compounds [1]. It not only inhibits the generation of reactive oxygen species by ultraviolet light but also prevents ultraviolet- and reactive oxygen species-induced DNA damage. Therefore, PLE extracts are a common ingredient in sun creams. A study in healthy participants showed that the fern extract is an effective chemophotoprotector against PUVA-induced skin phototoxicity [2]. To investigate if topically and orally PLE is really able to reverse severe actinic damage, a study including 131 patients with severe signs of photoaging and at least 3 AK lesions was performed [3].
Participants were randomised into 3 treatment groups. The first received topical photoprotection with SPF â„100 together with a topical PLE-preparation alone, the second group was treated in the same way plus the fern extract in an oral form once daily, and the third and control group only used the topical photoprotection. In case new AK lesions were noted, participants were permitted to undergo additional therapy, e.g. imiquimod or cryotherapy. At 12 months, skin changes were evaluated with reflectance confocal microscopy, and clinical changes by 2 different AK-specific scores and the appearance of new AK lesions or the need for specific AK interventions.
Data from 116 participants showed distinct improvements in the AK Field Assessment Scale Area (AK-FAS), especially in the arm also treated with the oral fern preparation: it improved by 26% compared with 4% in participants on topical PLE only, and a worsening by 13% in the control group. âIt is interesting that the control group that was given only common advice had increased photodamage and an increased number of new AK lesions,â said Dr Stefania Guida (Sapienza University of Rome, Italy) who presented the study results. In contrast, there were no new lesions in both PLE groups. Participants in both intervention groups improved in the Actinic Keratosis Area Score Index (AKASI) score by 7%, whereas there was a deterioration by 6% in the placebo arm (P<0.001).
Reflectance confocal microscopy supported this clinical data: 51% of those receiving the oral and local preparation of PLE and 45% of those receiving the local PLE preparation only had normalisation of the honeycomb pattern compared with 26% in the control group (P=0.04 for both comparisons). Also measured was a difference in the percentage of participants that needed additional therapy due to the occurrence of new lesions, which was necessary for 2% of participants taking both the oral and topical PLE preparation, in 11% of those only taking the topical PLE preparation, and in 38% of controls.
- Parrado C, et al. Int J Mol Sci 2016:17:pii:E1026.
- Middelkamp-Hup MA, et al. J Am Acad Dermato 2004:50:41-9.
- Pellacani G. Topical and topical plus oral immune photoprotection with Polypodium Leucotomos extract in severe actinic damage. A multicenter, randomised, prospective, assessor-blinded, 12-month controlled trial with confocal microscopy evaluation in 132 subjects. FC05.03, EADV Congress 2022, Milan, Italy, 7â10 September.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Novel oral psoriasis drug maintains efficacy over 2 years Next Article
Myths regarding âhealth benefitâ of suntan prevail in majority of population »
« Novel oral psoriasis drug maintains efficacy over 2 years Next Article
Myths regarding âhealth benefitâ of suntan prevail in majority of population »
Table of Contents: EADV 2022
Featured articles
Letter from the Editor
Psoriasis and Psoriatic Arthritis: What You Need to Know
Novel oral psoriasis drug maintains efficacy over 2 years
A3 adenosine receptor agonist showed modest efficacy but excellent tolerability
Selective IL-23 inhibitor achieves long-term disease control in many patients with active PsA
AI machine learning algorithm useful in early detection of PsA
Novel Developments in Sun Protection
Myths regarding âhealth benefitâ of suntan prevail in majority of population
Fern extract reverses severe actinic keratosis lesions
Vitiligo in 2022
Enhancing re-pigmentation rates with topical ruxolitinib in all body areas
Markedly lower skin cancer risk in vitiligo patients
Pruritus Treatment: Novel Agents Entering the Arena
Dupilumab leads to clinically relevant improvements in signs and symptoms of prurigo nodularis
Nalbuphine: aspiring to become another treatment for prurigo nodularis?
Notalgia paresthetica: may Îș-opioid receptor agonists be a long-awaited effective therapy?
Pharmacotherapy in Hidradenitis Suppurativa: New Opportunities
High potential for secukinumab as next biologic treatment for HS
Hidradenitis suppurativa: TYK2/JAK1 inhibitor shows promise
Best of the Posters
High rate of non- or partial responders jeopardises therapeutic success in HS
Genital psoriasis: high prevalence, often underdiagnosed
Decreased overall survival in melanoma patients with low vitamin D
News in Atopic and Seborrheic Dermatitis
Baricitinib possible therapeutic option for children with AD
Amlitelimab therapy leads to sustained decrease of IL-22 in AD patients
IL-13 inhibition with lebrikizumab shows high maintenance rates in AD
Does 8 weeks of emollients use prevent AD in high-risk infants?
Roflumilast foam led to high response rates in seborrheic dermatitis
What Is Hot in Hair Disorders?
Long-term improvement in alopecia areata with ritlecitinib therapy
Topical gel plus finasteride beneficial for patients with androgenetic alopecia
Deuruxolitinib achieves hair regrowth, even in patients with severe alopecia areata
Related Articles
November 5, 2022
Baricitinib possible therapeutic option for children with AD
November 5, 2022
Does 8 weeks of emollients use prevent AD in high-risk infants?
November 5, 2022
Long-term improvement in alopecia areata with ritlecitinib therapy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com